Pharmaceutical

RELIEF THERAPEUTICS Holding SA Announces the Closing of its Share Exchange Agreement with Sonnet BioTherapeutics, Inc. for the Divestment of its wholly-owned Subsidiary Relief Therapeutics SA

Thursday, April 2, 2020 - 7:16am

RELIEF THERAPEUTICS Holding SA (SIX:RLF, "Relief Holding") announces today the closing of the binding Share Exchange Agreement (SEA) for the acquisition by Sonnet BioTherapeutics, Inc. (Sonnet), now a subsidiary of Sonnet BioTherapeutics Holdings, Inc. (formerly known as Chanticleer Holdings, Inc.) (Nasdaq:SONN, "Sonnet Holdings") of Relief Therapeutics SA (Relief SA), a subsidiary of Relief Holding signed August 12, 2019.

Key Points: 
  • RELIEF THERAPEUTICS Holding SA (SIX:RLF, "Relief Holding") announces today the closing of the binding Share Exchange Agreement (SEA) for the acquisition by Sonnet BioTherapeutics, Inc. (Sonnet), now a subsidiary of Sonnet BioTherapeutics Holdings, Inc. (formerly known as Chanticleer Holdings, Inc.) (Nasdaq:SONN, "Sonnet Holdings") of Relief Therapeutics SA (Relief SA), a subsidiary of Relief Holding signed August 12, 2019.
  • As a consequence, Sonnet acquires all outstanding shares of Relief SA that becomes a wholly-owned Geneva-based subsidiary of Sonnet.
  • In counterpart, Sonnet paid to Relief Holding shares of its common stock that converted into 757,933 shares of listed Sonnet Holdings common stock.
  • This divestment will allow Relief Holding to focus its resources to further develop its main asset Aviptadil for pulmonary affections.

NOXXON Announces Completion of Patient Recruitment for the First Dose Cohort in the Phase 1/2 Brain Cancer Study Of NOX-A12 Plus Radiotherapy

Thursday, April 2, 2020 - 7:00am

The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients in a Phase 1/2 clinical trial.

Key Points: 
  • The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients in a Phase 1/2 clinical trial.
  • Under the approved protocol, it is planned that each patient is treated with NOX-A12 for up to six months.
  • The combination of NOX-A12 and radiotherapy has so far been well-tolerated by the patients that participated in this clinical trial.
  • In September 2019 the company initiated an additional trial with NOX-A12 in brain cancer in combination with radiotherapy.

Sensorion Reports Full-year 2019 Financial Results and Business Update

Thursday, April 2, 2020 - 6:30am

As part of this consortium, Sensorion will receive up to 5.6 million over the duration of the project contingent on milestones completion.

Key Points: 
  • As part of this consortium, Sensorion will receive up to 5.6 million over the duration of the project contingent on milestones completion.
  • SENS-111 (Seliforant) was safe and well tolerated in a Phase 2 proof-of-concept study for the treatment of acute unilateral vestibulopathy (AUV).
  • However, it did not meet the primary endpoint of vertigo intensity and Sensorion stopped all development activities for SENS-111.
  • On the 13th of March, Sensorion made an update on timelines for the ongoing Phase 2 study of SENS-401 to treat Sudden Sensorineural Hearing Loss (SSNHL).

Crossroads Treatment Centers Pioneers TeleVisits to Continue Seeing Patients During COVID-19 Crisis

Thursday, April 2, 2020 - 6:00am

Crossroads Treatment Centers , a category leader in outpatient treatment of Opioid Use Disorder, announced today that it will offer TeleVisit appointments throughout all of its Office-Based Opioid Treatment (OBOT) centers in Kentucky, New Jersey, Pennsylvania, and Virginia.

Key Points: 
  • Crossroads Treatment Centers , a category leader in outpatient treatment of Opioid Use Disorder, announced today that it will offer TeleVisit appointments throughout all of its Office-Based Opioid Treatment (OBOT) centers in Kentucky, New Jersey, Pennsylvania, and Virginia.
  • Crossroads is working on expanding TeleVisits to include counseling and toxicology, ensuring a comprehensive recovery program for its patients.
  • Maintaining access is a critical component of success for patients recovering from opioid addiction, said Trey Causey, M.D., Chief Medical Officer at Crossroads Treatment Centers.
  • Headquartered in Greenville, S.C., Crossroads Treatment Centers is a national leader in outpatient treatment for Opioid Use Disorder, operating over 90 addiction treatment facilities across 10 states.

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wednesday, April 1, 2020 - 9:30pm

The stock options approved under the Inducement Grants were issued pursuant to Dicernas 2016 Inducement Plan and have an exercise price per share equal to $17.33, the fair market value on the grant date.

Key Points: 
  • The stock options approved under the Inducement Grants were issued pursuant to Dicernas 2016 Inducement Plan and have an exercise price per share equal to $17.33, the fair market value on the grant date.
  • The stock options have a 10-year term and are subject to the terms and conditions of the applicable stock option agreements.
  • The Company granted the stock options and RSUs as inducement materials to the new employees entering into employment with Dicerna Pharmaceuticals, Inc. in accordance with Nasdaq listing Rule 5635(c)(4).
  • This press release includes forward-looking statements pertaining to continued service of employees and future vesting of inducement grants.

Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic

Wednesday, April 1, 2020 - 9:00pm

Merck will support its employees around the world who are uniquely qualified to provide medical services and wish to aid communities affected by the COVID-19 pandemic.

Key Points: 
  • Merck will support its employees around the world who are uniquely qualified to provide medical services and wish to aid communities affected by the COVID-19 pandemic.
  • Pfizer has created a new Global COVID-19 Medical Service Program that empowers medical colleagues to provide diagnostic, treatment, and public health support in the battle against COVID-19.
  • Lilly is deploying its medical professionals to staff a free drive-through COVID-19 testing facility at its corporate headquarters in Indianapolis.
  • Forward-Looking Statement of Eli Lilly and Company, Indianapolis, Ind., USA
    This release contains forward-looking statements regarding Lillys efforts in regard to the novel coronavirus.

Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic

Wednesday, April 1, 2020 - 9:00pm

Merck will support its employees around the world who are uniquely qualified to provide medical services and wish to aid communities affected by the COVID-19 pandemic.

Key Points: 
  • Merck will support its employees around the world who are uniquely qualified to provide medical services and wish to aid communities affected by the COVID-19 pandemic.
  • Pfizer has created a new Global COVID-19 Medical Service Program that empowers medical colleagues to provide diagnostic, treatment, and public health support in the battle against COVID-19.
  • Lilly is deploying its medical professionals to staff a free drive-through COVID-19 testing facility at its corporate headquarters in Indianapolis.
  • Forward-Looking Statement of Eli Lilly and Company, Indianapolis, Ind., USA
    This release contains forward-looking statements regarding Lillys efforts in regard to the novel coronavirus.

Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene

Wednesday, April 1, 2020 - 9:15pm

Zymeworks will receive a payment under its collaboration with BeiGene as a result of the achievement of this development milestone.

Key Points: 
  • Zymeworks will receive a payment under its collaboration with BeiGene as a result of the achievement of this development milestone.
  • We look forward to the results of these trials, which have the potential to further expand the population of patients who may benefit from ZW25.
  • Arm one of the trial will evaluate the safety, tolerability, and preliminary antitumor activity of ZW25 in combination with docetaxel in patients with metastatic HER2positive breast cancer.
  • Zymeworks lead clinical candidate, ZW25, is a novel Azymetric bispecific antibody currently in Phase 2 clinical development.

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wednesday, April 1, 2020 - 9:01pm

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that on March 31, 2020, the Compensation Committee of X4s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the 2019 Inducement Plan).

Key Points: 
  • X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that on March 31, 2020, the Compensation Committee of X4s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the 2019 Inducement Plan).
  • The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4.
  • The inducement awards consist of options to purchase an aggregate of 46,750 shares of X4s common stock and were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

Company Profile for Kubota Vision Inc. (dba of Acucela Inc.)

Wednesday, April 1, 2020 - 8:56pm

Kubota Vision Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide.

Key Points: 
  • Kubota Vision Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide.
  • Kubota Visions development pipeline include drug candidates for the treatment of diabetic retinopathy, Stargardt disease, and optogenetics-based gene therapy for the treatment of retinitis pigmentosa.
  • The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients.